Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial.

"Declaration of Competing Interests The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. JAS, LS, AD, KED, SGD, MAM, AM, RM, DR, AJR, and RU are shareholders of Raphael Labs LTD. JS is the managing director of Swales Pharma Consulting providing consulting services for a range of pharmaceutical companies. AJM and AR sit on the advisory board of Raphael labs."

"Funding statement The work was supported by Raphael labs LTD. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report."

"The Institutional Ethics Committees (IEC) for both Atharva Multispecialty Hospital and Research Centre (Ref:NIEC/INDT/APP/17/04/21/01) and Tulsi Hospital (Ref: THEC/CT/003/2021) approved the study. The trial was registered prospectively with The Clinical Trials Registry – India (CTRI) trial registration number: CTRI/2021/04/032,989."